Table 5.
True positive, true negative, sensitivity and specificity for CIN2+ per pathologists using ASC-H+ as cut-off
| Observer | TP | TN | FP | FN | SE (%) | SP (%) | AU (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|---|---|---|---|---|
| P1 (ref) | 28 | 56 | 12 | 4 | 87.5 | 82.4 | 85.0 | 70.0 | 93.3 |
| P2 | 30 | 48 | 20 | 2 | 93.81 | 70.62 | 82.2 | 60.0 | 96.01 |
| P3 | 24 | 54 | 14 | 8 | 75.0 | 79.4 | 77.2 | 63.2 | 87.1 |
| P4 | 23 | 65 | 3 | 9 | 71.9 | 95.61 | 83.8 | 88.51 | 87.8 |
| P5 | 22 | 54 | 14 | 10 | 68.8 | 79.4 | 74.1 | 61.1 | 84.4 |
| Mean (P2–P5) | 24.8 | 55.3 | 12.8 | 7.3 | 77.4 | 81.3 | 79.4 | 68.2 | 88.8 |
TP true positive, TN true negative, FP false positive, FN false negative, SE sensitivity, SP specificity, AU = AUROC = accuracy = (SE+SP)/2, PPV positive predictive value, NPV negative predictive value, ASC-H+ = ASC-H and HSIL, CIN2+ = CIN2, CIN3 and cancer
1Significantly higher than the average for P2–P5 (p<0.05)
2Significantly lower than the average for P2–P5 (p<0.05)